Phosphoinositide signalling regulates a series of important neuronal processes that are thought to be altered in mood disorders. Furthermore, mood-stabilizing drugs inhibit key enzymes that regulate phosphoinositide production and alter neuronal growth cone morphology in an inositol-reversible manner. Inositol is taken up by neurons from the extracellular fluid, presumably via membrane transporters; it can also be synthesized by the enzyme MIP-synthase (myo-inositol-1-phosphate synthase) and, in addition, it is generated by inositol phospholipid hydrolysis. The neuronal-specific HMIT (H + -myo-inositol transporter) represents a potential regulator of inositol signalling in neurons that warrants further investigation.
Background on bipolar disorder
BD (bipolar disorder) or manic depression is a severe and common psychiatric illness that is often treated with moodstabilizing drugs. Several molecular targets and signalling pathways have been implicated in the pathophysiology of the illness and in the mechanism of action of the drugs used to treat it. However, the precise targets that are responsible for the therapeutic action and side effects of the drugs are not known. Several molecules or pathways are known to be directly modulated by mood stabilizers including PKC (protein kinase C), ERK (extracellular-signal-regulated kinase)/MAPK (mitogen-activated protein kinase), GSK3β (glycogen synthase kinase 3β) and the phosphoinositide signalling pathway (the latter may represent a common pathway that is affected by several mood stabilizers). In the present review, we focus on some of the components of the phosphoinositide signalling pathway as possible drug targets.
The phosphoinositide signalling pathway
Clinical studies have revealed modest and often contradictory abnormalities in the phosphoinositide signalling pathway in individuals with BD. A magnetic resonance spectroscopy study showed that lithium treatment induced myo-inositol reduction in the frontal cortex of individuals with BD after 5 days of drug administration, at a time when the clinical state Key words: bipolar disorder, H + -myo-inositol transporter (HMIT), myo-inositol-1-phosphate synthase (MIP-synthase), phosphoinositide, sodium-myo-inositol transporter (SMIT).
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of the subjects was completely unchanged [1] . Furthermore, Silverstone et al. [2] did not observe any differences in myoinositol levels between control and individuals with BD; however, they showed that chronic treatment with both lithium and VPA (valproic acid) may normalize the altered phosphoinositide cycle activity observed in BD. Although these studies point to the involvement of the phosphoinositide cycle in BD, it is still not clear at which level it occurs.
Inositol phospholipids play a major role in receptormediated signal transduction pathways and are implicated in a diverse range of cellular processes in the central nervous system, such as enzyme activation, cytoskeletal changes, endocytosis, exocytosis, ion-channel activation and production of various second messengers [3] .
Activation of a variety of G-protein-linked neurotransmitter receptor subtypes and electrical activity [4] induce the hydrolysis of membrane phospholipids, particularly PtdIns(4,5)P 2 , by PLC (phospholipase C). PtdIns(4,5)P 2 is a key regulator of the actin cytoskeleton, and increased levels of presynaptic PtdIns(4,5)P 2 have been linked to abnormalities in both the presynaptic actin cytoskeleton and in the organization of the synaptic vesicle pool [5] . Hydrolysis of PtdIns(4,5)P 2 by PLC generates two second messengers: Ins(1,4,5)P 3 and DAG (diacylglycerol).
DAG activates PKC, which phosphorylates Munc-18 and, subsequently regulates the interaction of Munc-18 with syntaxin and the docking and/or the fusion of synaptic vesicles with the presynaptic plasma membrane.
In the cytosol, Ins(1,4,5)P 3 stimulates the mobilization of calcium from intracellular stores by binding to Ins(1,4,5)P 3 receptors in the ER (endoplasmic reticulum). Ins(1,4,5)P 3 can be phosphorylated by kinases to high-inositol phosphate molecules (ortho-and pyro-phosphate inositol), whose functions as intracellular messengers are still unclear as their levels do not seem to change in response to cell stimulation [6] . Ins(1,3,4,5,6)P 5 and InsP 6 are generally assumed to have 'housekeeping' functions rather than being second messengers [7] . Moreover, Ins(1,4,5)P 3 can be phosphorylated by Ins(1,4,5)P 3 3-kinase to Ins(1,3,4,5)P 4 , which is then dephosphorylated to Ins(1,3,4)P 3 . Ins(1,3,4,5)P 4 is a second messenger in its own right as it can influence Ins(1,4,5)P 3 -regulated calcium homoeostasis [8] . Ins(1,4,5)P 3 can be dephosphorylated to InsP 2 , InsP and myo-inositol by phosphatases. In particular, the IPPase (inositol polyphosphate-1-phosphatase) converts InsP 2 into InsP and the IMPase (inositol monophosphatase) dephosphorylates InsP (Ins1P, Ins3P or Ins4P) to myo-inositol.
Myo-inositol is a major brain osmolyte, mostly derived from diet. Dephosphorylated myo-inositol is incorporated into PtdIns and PtdIns(4,5)P 2 via a reaction involving activated PA (phosphatidic acid), named CDP-DAG (cytidine diphosphate diacylglycerol) [9] . More precisely, DAG is phosphorylated at the plasma membrane to PA via the action of DAG kinase; subsequently, PA is converted into CDP-DAG. PtdIns is converted into PtdInsP by PI4K (phosphoinositide 4-kinase) and into PtdIns(4,5)P 2 by the PI4P5K (phosphatidylinositol 4-phosphate 5-kinase) [10] . PtdIns is formed in the ER, and PITPs (phosphoinositidetransfer proteins) then transport the newly synthesized PtdIns to the plasma membrane [11] (Figure 1 ). How this pathway functions in synapses is unclear at present. The ability of a cell to maintain sufficient levels of myo-inositol is crucial for the resynthesis of phosphoinositides and for the maintenance and efficiency of signal transduction.
Mood stabilizers and the phosphoinositide signalling pathway
The three most frequently prescribed mood stabilizers (lithium, VPA and carbamazepine) have a common effect on the dynamic behaviour of rat sensory and cortical neurons. All three drugs inhibit the collapse and increase the spread area of growth cones, and, significantly, these effects are reversed by inositol, suggesting that all three mood-stabilizing drugs inhibit recycling of phosphoinositide [12, 13] .
Allison and Stewart [14] showed that lithium treatment resulted in a 30% reduction in myo-inositol concentration in the rat cerebral cortex, which was accompanied by an increase in InsP, suggesting that the drug inhibited the enzyme IMPase. It was subsequently confirmed that lithium inhibits IMPase directly with a K i of 0.8 mM [15] , which is within the therapeutic range of plasma concentrations of lithium (0.6-1.2 mM) [16] . Lithium appears to inhibit the enzyme following substrate hydrolysis by occupying the second magnesium-binding site before the phosphate group can dissociate from its interaction with the magnesium site [17] . There are at least two IMPase genes in mammals, IMPA1 and IMPA2 [18] , and it is still not clear whether functional differences exist between them. IMPA1 mRNA seems to be expressed at levels severalfold higher than does IMPA2, both in mouse and human frontal cortex [19] (also see Allen Brain Gene Atlas at http://www.brainatlas.org/). IMPA1 seems to be the predominant lithium-sensitive enzyme in the brain [20] [21] [22] . The inhibition by lithium is uncompetitive, which suggests that lithium does not bind to the enzyme directly, but rather to the enzyme-substrate complex. Furthermore, this may also suggest that lithium is most effective when substrate levels are high.
Lithium also directly inhibits the phosphatase immediately upstream of IMPase, known as IPPase, in an uncompetitive manner with a K i of 0.3 mM [22] . These findings suggest that the effects of lithium on phosphoinositide signalling are more pronounced in cells undergoing the highest rates of PtdIns(4,5)P 2 hydrolysis as opposed to quiescent cells [23] . Berridge et al. [7, 24] originally proposed the inositol depletion hypothesis in order to explain the efficacy of lithium in the treatment of BD. This theory was refined in 1995 to state that lithium lowers the rate of the phosphoinositide cycle rather than depleting intracellular concentrations of inositol [25] . In fact, it seems that inositol concentrations in neurons can reach millimolar levels, as it accumulates from the cerebrospinal fluid and the plasma, where inositol concentrations are ∼ 300 and ∼ 30 μM respectively [26, 27] .
The mood stabilizer VPA also modulates the phosphoinositide cycle, although via a different mechanism from lithium, as it does not affect IMPase and IPPase [28, 29] . In contrast with lithium, VPA decreases inositol phosphate levels [30] and it does so by decreasing the in vivo activity of MIP-synthase (myo-inositol-1-phosphate synthase) in mammalian brain (known as ino-1 in yeast) [19, 31] . MIP-synthase catalyses the conversion of D-glucose 6-phosphate into Dmyo-inositol 3-phosphate (also named L-myo-inositol 1phosphate [7] ). The reaction is NAD-dependent and activity is decreased 30-fold when inositol is added [32] . Post-mortem human brain MIP-synthase activity is inhibited indirectly in a non-competitive manner by VPA with a K i of 0.21 mM [31] . The purified recombinant human enzyme is, however, not inhibited directly by VPA [32] , suggesting either that a metabolite of VPA is the true inhibitor or that VPA targets an additional protein required for MIP-synthase activity. MIPsynthase protein has been reported to be expressed in the periphery in testes and, within the brain, to be associated mainly with the endothelium and the vasculature [33] (see Allen Brain Gene Atlas at http://www.brainatlas.org/); the involvement of MIP-synthase in the neuronal mechanism of action of mood stabilizers is therefore not clear.
Inositol transporters
SMITs (sodium-myo-inositol transporters)
Brain inositol levels are regulated via three main pathways: (i) synthesis from glucose 6-phosphate to inositol 1phosphate by the enzyme MIP-synthase, (ii) recycling from PtdIns(4,5)P 2 breakdown, and (iii) transport from the blood and cerebrospinal fluid. Key components of this third route are the inositol transporters, of which three are known. SMIT1 (SLC5A3) has been reported to be inhibited by lithium, VPA or carbamazepine after long-term treatment of astrocytes [34] . Moreover, all three mood stabilizers decreased SMIT1 mRNA levels in astrocytes dissected from different brain areas or in human astrocytoma cell lines, but only after prolonged treatment, indicating that SMIT1 may not be the primary target for the action of these drugs [35] . A more recent study by the same group showed increased SMIT1 mRNA levels in neutrophils from individuals with BD when compared with healthy subjects and decreased SMIT1 expression in neutrophils from individuals with BD treated with lithium [36] . The relevance and correlation of these findings to the brain are not clear. SMIT1 mRNA expression is increased in neural tissue following brain injury [37] ; moreover, in the mature brain, the highest levels of SMIT1 expression are in the choroid plexus [37] . SMIT1 expression is regulated by osmolarity [38] and it is expressed also in the periphery, especially in the kidney [39] . Lithium is known to induce kidney toxicity and this may be related to inhibition of SMIT [40] . SMIT1-null mutant mice die soon after birth due to central apnoea [41] . The fetuses have a ∼ 90% reduction in brain inositol levels with no change in PtdIns levels. Maternal treatment with inositol prevents lethality [42] . SMIT1-heterozygous mice did not show any obvious behavioural abnormalities (forced swim, amphetamine-induced hyperactivity, elevated plus maze, apomorphine-induced stereotypic climbing and lithiumpilocarpine seizure tests) [43] . These results led the authors to question the inositol depletion hypothesis [44] . However, when homozygotes were analysed, they behaved similarly to lithium-treated animals in the model of pilocarpine seizures and in the Porsolt forced swimming test model of depression [45] . In addition, a second sodium-dependent myo-inositol transporter has been described, SMIT2 (SLC5A13), which is widely distributed in peripheral tissues and also in the brain [46] . Little is known, however, about this isoform, except that it is regulated by osmolarity [47] .
HMIT (H + -myo-inositol transporter)
Uldry et al. [48] described a H + -dependent myo-inositol transporter, which has a more restricted tissue distribution than SMIT, and is expressed in several brain regions, including neurons in the frontal cortex and in the hippocampus [48] (see Allen Brain Gene Atlas at http://www.brainatlas.org/). Interestingly, HMIT appears to insert into the neuronal plasma membrane from a vesicular compartment in an activity-dependent manner, suggesting that HMIT may be involved in regulating neuronal phosphoinositide synthesis during periods of high activity [49] . It has been proposed that translocation of recombinant or endogenous HMIT to the plasma membrane may occur following, for example, neuronal depolarization or PKC activation [49] . HMIT is a glycosylated protein containing three conserved internalization signals: an ER retention signal and a dileucine internalization signal in the N-terminal region and a tyrosine-based internalization motif at the C-terminus [48] . Mutation of these retention signals is required for plasma membrane localization of the recombinant protein in Xenopus oocytes and mammalian cell lines and this surface localization correlated with functional inositol uptake into the cells [48] . Furthermore, HMIT is a symporter of myoinositol and protons, since inositol uptake was only evident under acidic extracellular conditions, associated with an inward electrical current and decreased intracellular pH [48] .
Future directions
Some evidence points to phosphoinositide signalling as the key pathway that is affected in BD and which may be a target for small-molecule intervention in order to restore the physiological balance in this disorder. In particular, it has been proposed that hyperactivation of the pathway may be linked with mania and decreased activity (inhibition of phosphoinositide recycling rather than decreased levels of inositol) with depression, and therefore normalization of the activity of this pathway may be key to mood stabilization [50] .
MIP-synthase and the inositol transporters SMIT1 and SMIT2 have been suggested as therapeutically relevant targets for the mood stabilizers. However, given that cortical neurons in culture do not express either the transporters or MIP-synthase [13] , mood stabilizers may modulate neuronal inositol signalling through interaction with other constituents of the pathway. The location of MIP-synthase in brain endothelial cells and the high levels of SMIT1 in the choroid plexus make it likely that both are involved in regulating the level of inositol in the brain, which is higher than in blood [51] . In contrast, HMIT is expressed predominantly in the brain, suggesting that it has a unique role in regulating brain inositol metabolism. In particular, HMIT is present in subsets of neurons in the cerebral cortex, an area implicated in mood control [48, 49] and in rat primary dissociated neurons [13] . The cellular location of HMIT has been reported to be regulated by neuronal activity, which may link the supply of inositol to activity of the phosphoinositide cycle [49] . However, little information on HMIT neuronal localization in resting and/or activated neurons is available at present and it is critical to determine whether this transporter is expressed at the plasma membrane, where it could transport inositol from the cerebrospinal fluid. Notably, HMIT structure suggests that this transporter has the molecular characteristics of an intracellular protein (for example, it contains an ER retention signal). As HMIT is also dependent on low pH for inositol transport, its physiological function merits further investigation.
